Vaccine最新文献

{"title":"Corrigendum to Assessment of the Bnt162b2 covid-19 vaccine immune response in Brazilian indigenous adolescents. Vaccine Volume 43, Part 1, 1 January 2025, 126494.","authors":"Laís Albuquerque de Oliveira, Isa Rita Brito de Morais, Silvana Beutinger Marchioro, Gabriel Barroso de Almeida, Gleyce Hellen de Almeida de Souza, Tiago da Silva Ferreira, Regina Rossoni, Dyjaene de Oliveira Barbosa, Vinicius João Navarini, Julio Croda, Alex José Leite Torres, Simone Simionatto","doi":"10.1016/j.vaccine.2024.126630","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126630","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126630"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Safety and Efficacy of inactivated COVID-19 vaccination in couples undergoing assisted reproductive technology: A prospective cohort study.","authors":"Juan Yang, Ying-Ling Yao, Xing-Yu Lv, Li-Hong Geng, Yue Wang, Enoch Appiah Adu-Gyamfi, Xue-Jiao Wang, Yue Qian, Ming-Xing Chen, Zhao-Hui Zhong, Ren-Yan Li, Qi Wan, Yu-Bin Ding","doi":"10.1016/j.vaccine.2024.126635","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126635","url":null,"abstract":"<p><strong>Background: </strong>The safety of the COVID-19 inactivated vaccine on pregnancy outcomes in couples undergoing assisted reproductive technology remains uncertain due to limited and speculative evidence. Existing studies primarily focus on the vaccination status of females, with scant information available regarding the vaccination status of male partners. Moreover, there is minimal research tracking live birth outcomes.</p><p><strong>Objective(s): </strong>The objective of this study was to evaluate the impact of COVID-19 inactivated vaccine administration on the outcomes of in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycles in infertile couples in China.</p><p><strong>Methods: </strong>This prospective cohort study involved couples undergoing IVF treatment at Sichuan Jinxin Xinan Women & Children's Hospital from August 2021 to September 2022. Based on whether they received vaccination before ovarian stimulation, the couples were divided into the vaccination group and the non-vaccination group. We compared the laboratory parameters and pregnancy outcomes between the two groups.</p><p><strong>Results: </strong>After performing propensity score matching (PSM), we observed similar live birth rates (41.23% vs. 44.08%, P = 0.555), clinical pregnancy rates (52.61% vs. 54.98%, P = 0.625), biochemical pregnancy (62.56% vs. 63.98%, P = 0.762), and ongoing pregnancy rates (49.76% vs. 51.18%, P = 0.770) between the vaccinated and unvaccinated women. Also, no significant disparities were found in terms of embryo development and laboratory parameters between the groups. Moreover, male vaccination had no impact on patients' pregnancy outcomes in assisted reproductive technology (ART) treatments (all P > 0.05). Additionally, there were no observable effects of vaccination on embryo development and pregnancy outcomes among couples undergoing ART (all P > 0.05).</p><p><strong>Conclusion(s): </strong>The findings suggest that COVID-19 vaccination did not have a significant effect on patients undergoing IVF/ICSI with fresh embryo transfer. Therefore, it is recommended that couples should receive COVID-19 vaccination as scheduled to help mitigate the COVID-19 pandemic.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126635"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Left out in the cold - inequity in infectious disease control due to cold chain disparity.","authors":"Aimee Talbot, Tania F de Koning-Ward, Daniel Layton","doi":"10.1016/j.vaccine.2024.126648","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126648","url":null,"abstract":"<p><p>Vaccines and diagnostic tools stand out as among the most influential advancements in public health, credited with averting an estimated 6 million deaths annually and substantially alleviating the burden of infectious disease. Despite this progress, the global imperative to prevent, detect, and combat infectious disease persists. Regrettably, hundreds of thousands of lives are still lost due to inadequate access to vaccines and diagnostics. A critical obstacle in accessibility lies in the requirement of reliable cold chain for their transportation and storage, a resource that remains inadequate in many regions, particularly in the developing world. Various factors, including socio-economic disparities, biological complexities, and manufacturing processes, exert significant influence on the availability and integrity of vaccines and diagnostic materials. This review aims to explore the multifaceted issue of inequality in access to disease control tools, examining the vulnerabilities of vaccines and diagnostics while also investigating recent advancements that offer promising solutions to improve thermal stability.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126648"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HPV vaccination and anal HPV infection in gay, bisexual, and other men who have sex with men.","authors":"Pareesa Kassam, Mariam El-Zein, Joseph E Tota, Pierre-Paul Tellier, François Coutlée, Alexandra de Pokomandy, Eduardo L Franco","doi":"10.1016/j.vaccine.2024.126644","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126644","url":null,"abstract":"<p><strong>Background: </strong>Gay, bisexual, and other men who have sex with men (gbMSM) have a higher risk of human papillomavirus (HPV) infection and related diseases and would benefit from preventive measures such as HPV vaccination. We assessed the association between HPV vaccination and anal HPV infection in HIV-negative gbMSM and gbMSM living with HIV from the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection study.</p><p><strong>Methods: </strong>Participants attended 7 visits over 12 months where they provided a nurse-collected anal sample and self-completed a questionnaire on risk factors and HPV vaccination. Samples were tested for HPV using polymerase chain reaction assays. We assessed the association with HPV vaccination and anal HPV prevalence and incidence using logistic and Cox regression, respectively. Analyses at the individual- (unit of analysis = participant) and HPV-level (unit of analysis = HPV type) considered vaccine-targeted types (any of HPVs 6/11/16/18) as the outcome. To assess construct validity, we repeated analyses considering incidence of non-vaccine-targeted (within- and cross-species) HPV types at the HPV-level. Estimates were adjusted for a propensity score to predict cumulative HPV positivity based on selected study and participant characteristics.</p><p><strong>Results: </strong>Of 258 enrolled participants (18.2-71.7 years; 69 being HIV-positive), 23.3 % were vaccinated at baseline. At the individual-level, there was no association between vaccination and HPVs 6/11/16/18 prevalence (n = 250, aOR = 1.12, 95 % CI = 0.56-2.22) or incidence (n = 152, aHR = 0.34, 95 % CI = 2.19 × 10^-18-1.38). At the HPV-level, while there was no association with HPVs 6/11/16/18 prevalence (n = 1000, aOR = 0.99, 95 % CI = 0.57-1.71), vaccination was associated with a reduction in HPVs 6/11/16/18 incidence (n = 754, aHR = 0.22, 95 % CI = 6.01 × 10^-18-0.79). Vaccination was not associated with incidence of within-species (n = 2299, aHR = 0.76, CI = 0.42-1.24) or cross-species (n = 3774, aHR = 1.28, CI = 0.89-1.85) HPV types. Results were similar by HIV status.</p><p><strong>Conclusion: </strong>Our findings support that HPV vaccination protects against incident anal infection of vaccine-targeted HPV types, thus, gbMSM should be encouraged to get vaccinated against HPV.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126644"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the toxoplasma Urm1 gene deletion mutant (PruΔUrm1) as a promising vaccine candidate against toxoplasmosis in mice.","authors":"Shu Bian, Qingxiu Cai, Shujing Wang, Ying Xie, Nianyuan Chen, Qingyang Song, Hongmei Li, Ningning Zhao, Xiao Zhang","doi":"10.1016/j.vaccine.2024.126632","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126632","url":null,"abstract":"<p><p>Toxoplasmosis is a significant zoonotic disease that poses a serious threat to both human and animal health. Despite ongoing research, developing an effective vaccine for toxoplasmosis remains a challenge. In this study, we evaluated the vaccine potential of the Toxoplasma Urm1 gene deletion mutant (PruΔUrm1) by assessing its pathogenicity and protective efficacy in mice. Using CRISPR/Cas9 technology, we successfully created a type II Toxoplasma gondii Pru mutant strain with a deleted Urm1 gene. Compared to the wild-type parasite, the PruΔUrm1 strain exhibited significantly reduced invasive and proliferative abilities in vitro. In in vivo studies, mice intraperitoneally infected with the parental Pru strain showed severe symptoms including emaciation, hunching, and high mortality rates. In contrast, mice infected with PruΔUrm1 tachyzoites demonstrated a 100 % survival rate, no overt symptoms, and a markedly reduced parasite burden in the liver, spleen, and lungs, indicating reduced pathogenicity. Notably, PruΔUrm1 vaccination triggered a strong immune response, characterized by significantly elevated cytokine levels, including TNF-α, IFN-γ and IL-10. Furthermore, we assessed the immunoprotective efficacy of PruΔUrm1 vaccination in mice against type I strains. Mice immunized with PruΔUrm1 were able to resist the tachyzoites of type I RH wild-type parasites, achieving a 100 % survival rate and significantly reduced parasite loads in the liver, spleen and lungs. These data demonstrate that PruΔUrm1 immunization provides effective protection against acute Toxoplasma infections and holds promise as a potential vaccine candidate for toxoplasmosis.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126632"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structural equation modeling to evaluate the adult vaccine hesitancy scale for vaccines recommended during pregnancy.","authors":"Tasmiah Nuzhath, Yingwei Yang, Marie-Claude Couture, Ning Yan Gu, Jeannette L Comeau, Annette K Regan","doi":"10.1016/j.vaccine.2024.126568","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126568","url":null,"abstract":"<p><strong>Introduction: </strong>Acceptance of recommended vaccines is lower among pregnant people compared to non-pregnant adults, yet no tool has specifically measured prenatal vaccine hesitancy. We evaluated the performance of an existing adult Vaccine Hesitancy Scale (aVHS) in measuring vaccine hesitancy toward routinely recommended prenatal vaccines.</p><p><strong>Methods: </strong>Between December 2021 and April 2022, we conducted a cross-sectional national online survey with 917 US postpartum adults 18-49 years old who had given birth in the past six months. Vaccine hesitancy was measured using the aVHS, a 10-item scale previously validated among the adult general population. Scores range from 10 to 50, with higher scores indicating greater vaccine hesitancy. Structural equation modeling (SEM) with weighted least squares means and variances adjusted (WLSMV) estimator was used to assess the fit of the aVHS structure. Construct validity was assessed by examining the correlation between the aVHS score and the self-reported receipt of recommended prenatal vaccines.</p><p><strong>Results: </strong>SEM indicated acceptable fit (RMSEA: 0.098; CFI: 0.983; TLI: 0.978; SRMR: 0.040) of the data to the two-factor model: (1) lack of vaccine confidence, and (2) perceived vaccine risks. For the paths from the two factors to the vaccine acceptance, lack of vaccine confidence was significantly correlated with influenza vaccine acceptance (β = -0.41, p < 0.001) and COVID-19 vaccine acceptance (β = -0.64, p < 0.001), while perceived vaccine risk was significantly linked with Tdap vaccine acceptance (β = -0.57, p < 0.001) and influenza vaccine acceptance (β = -0.25, p < 0.001). Additionally, pregnant people with higher aVHS scores were less likely to receive recommended prenatal vaccines.</p><p><strong>Discussion: </strong>Although the aVHS offered acceptable measurement of prenatal vaccine hesitancy, a scale that measures pregnancy-specific concerns may offer more tailored measurement for this unique population.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126568"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States.","authors":"Jenny W Sun, Laura E Dodge, Eric J Kim, Li Zhou, Susan Mather, Henry Goebe, Nicola Charpentier, Kirsten Nespithal, Kofi Asomaning, Florence T Wang","doi":"10.1016/j.vaccine.2024.126629","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126629","url":null,"abstract":"<p><strong>Background: </strong>Limited data exists regarding the safety of the COVID-19 2023-2024 vaccine formulations and whether the safety profiles differ from the original formulations. We evaluated the association between the BNT162b2 XBB COVID-19 vaccine and the risk of 20 pre-specified adverse events of special interest (AESIs).</p><p><strong>Methods: </strong>We identified commercially-insured individuals in the US age ≥ 6 months who received the BNT162b2 XBB COVID-19 vaccine between September 11, 2023 and January 15, 2024 within the Optum pre-adjudicated database. The self-controlled risk interval design was used to compare the incidence of 20 pre-specified AESIs during a risk period following vaccination to a control period. Relative incidence and 95 % confidence intervals (CI) were estimated using exact conditional Poisson regression.</p><p><strong>Results: </strong>The analysis included 113,459 individuals who received the BNT162b2 XBB COVID-19 vaccine (median [interquartile range] age: 47.1 [33.0-59.1] years). Relative incidence was calculated when ≥1 event occurred in either the risk or control period. For these 10 AESIs, there was no significant association between receipt of the BNT162b2 XBB COVID-19 vaccine and the incidence of any of these AESIs. Point estimates were higher in the risk period compared to the control period for ischemic stroke (relative incidence: 1.52; 95 % CI: 0.44-5.94), myocarditis/pericarditis (relative incidence: 1.50; 95 % CI: 0.22-12.61), immune-mediated myositis (relative incidence: 1.44; 95 % CI: 0.83-2.52), herpes zoster (relative incidence: 1.24; 95 % CI: 0.69-2.28), and non-febrile convulsions/seizures (relative incidence: 1.22; 95 % CI: 0.86-1.73). These estimates were not statistically significant, though most were based on few events. Results were generally similar in subgroup analyses of individuals administered a concomitant seasonal influenza vaccine.</p><p><strong>Conclusions: </strong>There was no increased risk of 20 pre-specified AESIs following receipt of the BNT162b2 XBB COVID-19 vaccine among US commercially insured individuals aged ≥6 months. Findings are consistent with the current evidence on the safety of BNT162b2 COVID-19 vaccines. Public registration: EUPAS108135.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126629"},"PeriodicalIF":0.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"School vaccination programmes to increase HPV vaccination coverage - Experiences from Bremen, Germany.","authors":"Regina Singer, Imke Hübotter, Franziska Hölzner, Christine Genedl, Lutz Jasker, Niels Michalski, Christiane Piepel, Thorsten Rieck, Günter Tempel, Ole Wichmann, Anja Takla","doi":"10.1016/j.vaccine.2024.126636","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126636","url":null,"abstract":"<p><p>Germany primarily relies on a practice-based, opportunistic immunisation system. Despite the introduction of the Human papillomavirus (HPV) vaccine into the German vaccination schedule in 2007, coverage remains low. International experience suggests that school-based vaccination can increase HPV coverage. Therefore, in 2013/14 Bremen's public health department offered HPV vaccinations within a school programme, targeting all 8th-graders. We aimed to evaluate the programme, with a focus on vulnerable groups. In a retrospective cohort design, we analysed vaccination status and uptake among all 8th-graders from 2015/16 to 2018/19 (girls) and 2022/23 (girls and boys). Sub-analyses were based on the School Social Index (SSI), which ranges from 1 (higher socio-economic position, SEP) to 5 (lower SEP), considering factors like poverty, migration, and living environment. The study included 13,550 students from 1,440 classes in 56 schools. Among previously unvaccinated students, 26-35 % of girls and 39 % of boys annually accepted and received the school-based HPV vaccination. Uptake was higher among students from lower as compared to higher SEP schools (SSI 5: 37 % vs. SSI 1: 30 %, p = 0.022). Vaccine uptake among unvaccinated students remained stable over time, with one-third receiving at least one HPV vaccination at school. The remaining two-thirds of unvaccinated did not make use of the vaccination offer at school. It needs to be investigated if this is possibly due to vaccine hesitancy or a preference for practice-based vaccinations. While school vaccination programmes can improve uptake, implementing a nationwide programme in Germany will be challenging and may not address all existing major uptake barriers.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126636"},"PeriodicalIF":0.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing of rejection events preceded by Covid-19 mRNA vaccination in recipients of solid organ transplants.","authors":"Quentin Perrier, Johan Noble, Agnès Bonadona, Caroline Augier, Thomas Jouve, Aude Boignard, Loïc Falque, Salomé Gallet, Pierrick Bedouch, Lionel Rostaing, Olivier Epaulard","doi":"10.1016/j.vaccine.2024.126617","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126617","url":null,"abstract":"<p><strong>Objectives: </strong>SARS-CoV-2 mRNA vaccine reactogenicity has raised concerns regarding the risk of rejection in solid organ transplant recipients. We explored whether SOT recipients diagnosed with acute rejection had previously received a vaccine injection within a timeframe consistent with a causal link.</p><p><strong>Methods: </strong>We identified all SOT recipients with a diagnosis of acute rejection from 2020 to 2022 and who had previously received a SARS-CoV-2 vaccination, and analysed whether the delay between vaccination and rejection was constant.</p><p><strong>Results: </strong>In the 45 identified patients, median delay between the last SARS-CoV-2 vaccination and the rejection was 102 days [IQR 48-178]; the continuous distribution of this delay, with no identifiable time pattern, is not in favor of a role of vaccination in rejection.</p><p><strong>Conclusion: </strong>SARS-CoV-2 mRNA vaccination is unlikely to trigger rejection in SOT recipients.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126617"},"PeriodicalIF":0.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Describing COVID-19 immunizations for First Nations people on-reserve in Alberta using real-time integration of point of care and provincial data.","authors":"Dean T Eurich, Olivia Weaver, Cathleen McDermott, Allison Soprovich, Lisa A Wozniak, Beth Woytas, Chris Sarin, Lauren Bilinsky, Parminder Thiara, Celine O'Brien, Lea Bill, Lynden Crowshoe, Ambikaipakan Senthilselvan, Salim Samanani","doi":"10.1016/j.vaccine.2024.126614","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126614","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 profoundly impacted First Nation peoples. Historically, records of on- and off-reserve vaccine delivery have been fragmented. For the first time in Canada, we aimed to describe complete immunization rates, on- and off-reserve vaccine delivery, for COVID-19 in Alberta, Canada among First Nations on-reserve.</p><p><strong>Methods: </strong>Fifteen First Nations in Alberta, Canada participated in this prospective, descriptive cohort study whereby real-time integration (RTI) was deployed to reconcile COVID-19 vaccine delivery records on-reserve (local database) to those reported off-reserve (provincial database) between January 3, 2021-December 1, 2022. Immunization data (individuals ≥ 6 months) were aggregated into 100 one-week intervals. Weekly immunization rates were assessed by age, sex, community size, and location of vaccine administration (on- or off-reserve) using multiple linear regressions and chi2 tests.</p><p><strong>Findings: </strong>50,758 First Nation people were included, approximately 50% of whom were female. RTI data showed that 64% received at least one dose of vaccine with higher rates in older First Nation adults. No sex differences were observed. Nearly half received their first dose off-reserve and would have been missed by local public health on-reserve (local database) without the implementation of RTI. First dose immunization rates rapidly increased with graduated First Nation-specific eligibility and provincial incentives promoting uptake (p < 0.001).</p><p><strong>Interpretation: </strong>We accurately assessed complete immunization rates among First Nation people receiving services on-reserve irrespective of delivery of immunizations on- or off-reserve through deployment of an innovative RTI approach. Without these RTI advances, immunization rates would have been substantially under-reported and may have misdirected public health initiatives around vaccine uptake. RTI should be a priority for all provinces in Canada to ensure accurate coverage rates for First Nation people.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126614"},"PeriodicalIF":0.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}